Literature DB >> 19451858

The clinical burden of tuberculosis among human immunodeficiency virus-infected children in Western Kenya and the impact of combination antiretroviral treatment.

Paula Braitstein1, Winstone Nyandiko, Rachel Vreeman, Kara Wools-Kaloustian, Edwin Sang, Beverly Musick, John Sidle, Constantin Yiannoutsos, Samwel Ayaya, E Jane Carter.   

Abstract

CONTEXT: The burden of tuberculosis (TB) disease in children, particularly in HIV-infected children, is poorly described because of a lack of effective diagnostic tests and the emphasis of public health programs on transmissible TB.
OBJECTIVES: The objectives of this study were to describe the observed incidence of and risk factors for TB diagnosis among HIV-infected children enrolled in a large network of HIV clinics in western Kenya.
DESIGN: Retrospective observational study.
SETTING: The USAID-Academic Model Providing Access to Healthcare (AMPATH) Partnership is Kenya's largest HIV/AIDS care system. Since 2001, the program has enrolled over 70,000 HIV-infected patients in 18 clinics throughout Western Kenya. PATIENTS: This analysis included all HIV-infected children aged 0 to 13 years attending an AMPATH clinic. MAIN OUTCOME MEASURE: The primary outcome was a diagnosis of any TB, defined either by a recorded diagnosis or by the initiation of anti-TB treatment. Diagnosis of TB is based on a modified Kenneth Jones scoring system and is consistent with WHO case definitions.
RESULTS: There were 6535 HIV-infected children aged 0 to 13 years, eligible for analysis, 50.1% were female. Of these, 234 (3.6%) were diagnosed with TB at enrollment. There were subsequently 765 new TB diagnoses in 4368.0 child-years of follow-up for an incidence rate of 17.5 diagnoses (16.3-18.8) per 100 child-years. The majority of these occurred in the first 6 months after enrollment (IR: 106.8 per 100 CY, 98.4-115.8). In multivariable analysis, being severely immune-suppressed at enrollment (Adjusted Hazard Ratio [AHR]: 4.44, 95% CI: 3.62-5.44), having ever attended school AHR: 2.65, 95% CI: 2.15-3.25), being an orphan (AHR: 1.57, 95% CI: 1.28-1.92), being severely low weight-for-height at enrollment (AHR: 1.46, 95% CI: 1.32-1.62), and attending an urban clinic (AHR: 1.39, 95% CI: 1.16-1.67) were all independent risk factors for having an incident TB diagnosis. Children receiving combination antiretroviral treatment were dramatically less likely to be diagnosed with incident TB (AHR: 0.15, 95% CI: 0.12-0.20).
CONCLUSIONS: These data suggest a high rate of TB diagnosis among HIV-infected children, with severe immune suppression, school attendance, orphan status, very low weight-for-height, and attending an urban clinic being key risk factors. The use of combination antiretroviral treatment reduced the probability of an HIV-infected child being diagnosed with incident TB by 85%.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19451858     DOI: 10.1097/INF.0b013e31819665c5

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  26 in total

Review 1.  Unresolved antiretroviral treatment management issues in HIV-infected children.

Authors:  Shirin Heidari; Lynne M Mofenson; Charlotte V Hobbs; Mark F Cotton; Richard Marlink; Elly Katabira
Journal:  J Acquir Immune Defic Syndr       Date:  2012-02-01       Impact factor: 3.731

2.  Impact of expanded antiretroviral use on incidence and prevalence of tuberculosis in children with HIV in Kenya.

Authors:  L L Abuogi; C Mwachari; H H Leslie; S B Shade; J Otieno; N Yienya; L Sanguli; E Amukoye; C R Cohen
Journal:  Int J Tuberc Lung Dis       Date:  2013-10       Impact factor: 2.373

3.  Risk factors for mortality in Malawian children with human immunodeficiency virus and tuberculosis co-infection.

Authors:  W C Buck; D Olson; M M Kabue; S Ahmed; L K Nchama; A Munthali; M C Hosseinipour; P N Kazembe
Journal:  Int J Tuberc Lung Dis       Date:  2013-11       Impact factor: 2.373

4.  Tuberculosis in HIV programmes in lower-income countries: practices and risk factors.

Authors:  L Fenner; M Forster; A Boulle; S Phiri; P Braitstein; C Lewden; M Schechter; N Kumarasamy; M Pascoe; E Sprinz; D R Bangsberg; P S Sow; D Dickinson; M P Fox; J McIntyre; M Khongphatthanayothin; F Dabis; M W G Brinkhof; R Wood; M Egger
Journal:  Int J Tuberc Lung Dis       Date:  2011-05       Impact factor: 2.373

5.  The burden of vaccine-preventable diseases among HIV-infected and HIV-exposed children in sub-Saharan Africa: a systematic review and meta-analysis.

Authors:  Olatunji O Adetokunboh; Ajibola Awotiwon; Duduzile Ndwandwe; Olalekan A Uthman; Charles S Wiysonge
Journal:  Hum Vaccin Immunother       Date:  2019-05-22       Impact factor: 3.452

6.  Prevalence of and risk factors for pulmonary tuberculosis among newly diagnosed HIV-1 infected Nigerian children.

Authors:  Augustine O Ebonyi; Stephen Oguche; Emeka U Ejeliogu; Oche O Agbaji; Nathan Y Shehu; Isaac O Abah; Atiene S Sagay; Placid O Ugoagwu; Prosper I Okonkwo; John A Idoko; Phyllis J Kanki
Journal:  Germs       Date:  2016-03-01

7.  Tuberculosis in human immunodeficiency virus-infected children starting antiretroviral therapy in Côte d'Ivoire.

Authors:  A F Auld; M Z Tuho; K A Ekra; J Kouakou; R W Shiraishi; G Adjorlolo-Johnson; R Marlink; T V Ellerbrock
Journal:  Int J Tuberc Lung Dis       Date:  2014-04       Impact factor: 2.373

8.  The hidden harm of home-based care: pulmonary tuberculosis symptoms among children providing home medical care to HIV/AIDS-affected adults in South Africa.

Authors:  Lucie Cluver; Mark Orkin; Mosa Moshabela; Caroline Kuo; Mark Boyes
Journal:  AIDS Care       Date:  2013-03-04

9.  Incident tuberculosis and risk factors among HIV-infected children in Tanzania.

Authors:  Nan Li; Karim P Manji; Donna Spiegelman; Aisa Muya; Ramadhani S Mwiru; Enju Liu; Guerino Chalamilla; Wafaie W Fawzi; Christopher Duggan
Journal:  AIDS       Date:  2013-05-15       Impact factor: 4.177

10.  Comparison of mantoux and tine tuberculin skin tests in BCG-vaccinated children investigated for tuberculosis.

Authors:  Wenli Pan; Lyness Matizirofa; Lesley Workman; Tony Hawkridge; Willem Hanekom; Hassan Mahomed; Gregory Hussey; Mark Hatherill
Journal:  PLoS One       Date:  2009-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.